Autonomix Medical AMIX 深 沪
交易中 10-06 10:33:59 美东时间
3.5312
-0.009
-0.25%
华盛通- 最 高9.99
- 今 开3.54
- 成交量 2.90万股
- 最 低 3.47
- 昨 收 3.54
- 总市值 0
- 52周最高 24.68
- 市盈率 静 --
- 换手率 Infinity.00%
- 52周最低 0.2002
- 委 比 92.80%
- 总股本 --
- 历史最高 24.68
- 量 比 0.36
- 振 幅 184.18%
- 历史最低 0.2002
- 每 手 1
- 风险率 2.66%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Autonomix Medical Receives Canadian Patent For 'Endoscopic Sympathectomy Systems And Methods'
The newly issued patent expands and reinforces Autonomix's intellectual property estate related to real-time nerve sensing, mapping, physiological monitoring, and feedback-guided neuromodulation technologies. The
07-13 19:31
Autonomix Medical Announces 1-For-21 Reverse Stock Split, Effective June 24
Autonomix Medical, Inc. (NASDAQ:AMIX) ("Autonomix" or the "Company"), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced that it filed an amendment to its amended and
06-19 04:31
Silver Rises Sharply; Chicago PMI Surges In December
U.S. stocks traded lower midway through trading, with the Dow Jones index falli...
2025-12-31 01:03
Autonomix Medical Secures New European Patent For Precision Cardiac Neuromodulation
With over 80 issued patents and 39 pending patent applications, Autonomix is building a comprehensive, global IP portfolio in nerve-sensing and modulationNewly granted patent further strengthens the Company's strategic
2025-12-30 21:32
Nasdaq Turns Higher; NY Manufacturing Activity Surges In November
U.S. stocks traded mostly higher midway through trading, with the Nasdaq Compos...
2025-11-18 01:31
Autonomix Medical, Inc. Granted Approval to Expand Proof-of-Concept Human Clinical Study, Doubling Potential Addressable Market Beyond Pancreatic Cancer Pain
Autonomix Medical, Inc. has received ethics committee approval to expand its clinical trial into visceral cancer pain, building on initial success in pancreatic cancer pain. The PoC 2 phase aims to evaluate the safety and effectiveness of its proprietary ablation technology. The Company expects to begin patient enrollment in June 2025, supporting its strategy to address multiple cancer indications and create long-term value through platform expansion.
2025-06-05 12:45
Autonomix Shows Preliminary Results in Nerve Ablation Trial for Pancreatic Cancer Pain
Autonomix Medical, Inc. (NASDAQ:AMIX) ("Autonomix" or the "Company"), a medical device company focused on advancing precision nerve-targeted treatments, today announced 4-6 week preliminary positive results from the
2024-09-09 19:02
--Ladenburg Thalmann Initiates Autonomix Medical at Buy With $1.40 Price Target
07:40 AM EDT, 09/03/2024 (MT Newswires) -- Price: 0.6432, Change: -0.03, Percent Change: -4.00
2024-09-03 19:40
12 Health Care Stocks Moving In Monday's Intraday Session
Gainers Theriva Biologics (AMEX:TOVX) shares moved upwards by 25.0% to $5.88 during Monday's regular session. The company's market cap stands at $5.9 million. WORK Medical Technology (NASDAQ:WOK) stock moved upwards by 24.49% to $4.89. The company's market cap stands at $70.9 million. Cingulate (NAS...
2024-09-03 00:30
Autonomix Medical Technology And Interim Clinical Trial Filings To Be Featured In Podium Presentation At 2024 CIRSE Annual Congress
Presentation to discuss latest developments in future AI applications in interventional radiology, specifically highlighting the early results from the Company's ongoing proof-of-concept (PoC) human clinical trial
2024-08-21 20:36
